Hendra Stevie Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hendra Stevie Tan has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Marco Mura
Department of Translational Medicine and for Romagna, University of Ferrara, 44121 Ferrara, Italy
16 shared publications H. Collewijn
Department of Physiology I, Faculty of Medicine, Erasmus UniversityRotterdam, The Netherlands
9 shared publications- Johannes van der Steen
Department of Neuroscience, Erasmus MC, Rotterdam, The Netherlands
8 shared publications - Jenny Annemieke Nij Bijvank
Amsterdam UMC, Department of Neurology, Vrije Universiteit Amsterdam, MS Centre and Neuro-ophthalmology Expertise Centre Amsterdam, Amsterdam Neuroscience , 1081 HZ Amsterdam , The Netherlands
7 shared publications Sarit Y. Lesnik Oberstein
From the Department of Ophthalmology, Academic Medical Center, University of Amsterdam, The Netherlands
7 shared publicationsHeico M. Bijl
From the Department of Ophthalmology, Academic Medical Center, University of Amsterdam, The Netherlands
6 shared publications
Latest Publications
- Open Access
- 22 January 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (2)
Ophthalmologic Evaluation and Clinical Outcome in Candidemia: A 7-Year Retrospective Multicenter Cohort Study
Background: Ocular candidiasis (OC) is a notorious complication of candidemia, but guidelines on fundoscopic screening are inconsistent. We aimed to determine the frequency of OC in patients with candidemia who underwent fundoscopy, regardless of visual symptoms, and to evaluate its impact on antifungal treatment selection and duration. Methods: A retrospective cohort study was performed at 2 tertiary care hospitals in the Netherlands in adult patients with at least 1 positive blood culture with Candida species between January 2018 and December 2024. Primary outcomes were the incidence of OC (defined as proven or probable chorioretinitis or endophthalmitis), persistent vision loss, and changes in the choice and/or duration of antifungal therapy in patients with OC. Results: Of 402 patients, 307 (76.4%) underwent fundoscopy. Ocular candidiasis was diagnosed in 15 of 307 patients (4.9%), including 12 with probable chorioretinitis (3.9%) and 3 with probable endophthalmitis (1.0%). Nine of the 15 patients (60%) were asymptomatic (n = 6) or unable to report symptoms (n = 3). In all 15 patients, the fundoscopic findings resulted in a change in therapy. This consisted of therapy prolongation (n = 15), addition of (n = 7) or switch to (n = 4) an azole, and intravitreal antifungal injections (n = 2). Persistent visual impairment of any degree occurred in 3 of 15 patients (20%), all of whom were initially symptomatic. Conclusions: Ocular candidiasis is a relatively rare but clinically significant complication of candidemia. Fundoscopic findings are used to guide treatment decisions. Persistent vision loss was uncommon.
- 22 January 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (2)
Open AccessOphthalmologic Evaluation and Clinical Outcome in Candidemia: A 7-Year Retrospective Multicenter Cohort Study
Background: Ocular candidiasis (OC) is a notorious complication of candidemia, but guidelines on fundoscopic screening are inconsistent. We aimed to determine the frequency of OC in patients with candidemia who underwent fundoscopy, regardless of visual symptoms, and to evaluate its impact on antifungal treatment selection and duration. Methods: A retrospective cohort study was performed at 2 tertiary care hospitals in the Netherlands in adult patients with at least 1 positive blood culture with Candida species between January 2018 and December 2024. Primary outcomes were the incidence of OC (defined as proven or probable chorioretinitis or endophthalmitis), persistent vision loss, and changes in the choice and/or duration of antifungal therapy in patients with OC. Results: Of 402 patients, 307 (76.4%) underwent fundoscopy. Ocular candidiasis was diagnosed in 15 of 307 patients (4.9%), including 12 with probable chorioretinitis (3.9%) and 3 with probable endophthalmitis (1.0%). Nine of the 15 patients (60%) were asymptomatic (n = 6) or unable to report symptoms (n = 3). In all 15 patients, the fundoscopic findings resulted in a change in therapy. This consisted of therapy prolongation (n = 15), addition of (n = 7) or switch to (n = 4) an azole, and intravitreal antifungal injections (n = 2). Persistent visual impairment of any degree occurred in 3 of 15 patients (20%), all of whom were initially symptomatic. Conclusions: Ocular candidiasis is a relatively rare but clinically significant complication of candidemia. Fundoscopic findings are used to guide treatment decisions. Persistent vision loss was uncommon.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S14)
Longitudinal retinal microvascular changes in preclinical Alzheimer’s disease
Background: The retina has become an area of increasing interest as a potential biomarker for neurodegeneration, as it is easily accessible and patient friendly. Previous studies have shown changes in the vasculature of the retina in patients with mild cognitive impairment (MCI) and Alzheimer’s disease (AD) in a cross sectional design. In this study we explore longitudinal retinal microvascular changes in amyloid beta positive (AB +) participants compared with amyloid beta negative (AB‐) participants.Method: We analysed data from 159 cognitively normal participants (mean age 70.6 SD ± 5.91, 55% females) for changes in four microvascular parameters at baseline and 2 year follow up. (mean time between visits 2.2 years ± 0.23 SD) (Table 1) Amyloid status was obtained from positron emission tomography scans (PET) performed in both 2015 and 2019. The Cirrus 5000 Optical Coherence Tomography Angiography (OCT‐A) was used to obtain baseline and follow up measurements of the optic nerve head (ONH) and macula.Result: In total, data from 123 AB‐ participants and 37 AB+ participants were included in the analysis. AB (+) participants were further divided into converters (AB‐+,n = 19) and those positive on both PET scans. (AB ++, n = 18) A decrease in vessel density (VD) of the ONH in AB++ participants was demonstrated over time, (p = 0.04) however no change over time was found for VD in the macula inner and outer ring or foveal avascular zone (FAZ). (Figure 2) The VD was found to be consistently higher amongst AB++ participants in the macula inner and outer rings (p<0.05) and the FAZ area was higher in AB‐+ participants. (p<0.05)Conclusion: This study showed change in VD over time for the ONH region in participants who have been AB + for 4 years or longer. These participants further demonstrated a higher VD in the macula inner and outer rings compared to AB—and AB‐+ participants. Additional longitudinal studies where amyloid status is present for longer periods of time amongst cognitively healthy participants should be undertaken to see if these OCTA microvascular changes could be used as a biomarker in preclinical AD.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S14)
Open AccessLongitudinal retinal microvascular changes in preclinical Alzheimer’s disease
Background: The retina has become an area of increasing interest as a potential biomarker for neurodegeneration, as it is easily accessible and patient friendly. Previous studies have shown changes in the vasculature of the retina in patients with mild cognitive impairment (MCI) and Alzheimer’s disease (AD) in a cross sectional design. In this study we explore longitudinal retinal microvascular changes in amyloid beta positive (AB +) participants compared with amyloid beta negative (AB‐) participants.Method: We analysed data from 159 cognitively normal participants (mean age 70.6 SD ± 5.91, 55% females) for changes in four microvascular parameters at baseline and 2 year follow up. (mean time between visits 2.2 years ± 0.23 SD) (Table 1) Amyloid status was obtained from positron emission tomography scans (PET) performed in both 2015 and 2019. The Cirrus 5000 Optical Coherence Tomography Angiography (OCT‐A) was used to obtain baseline and follow up measurements of the optic nerve head (ONH) and macula.Result: In total, data from 123 AB‐ participants and 37 AB+ participants were included in the analysis. AB (+) participants were further divided into converters (AB‐+,n = 19) and those positive on both PET scans. (AB ++, n = 18) A decrease in vessel density (VD) of the ONH in AB++ participants was demonstrated over time, (p = 0.04) however no change over time was found for VD in the macula inner and outer ring or foveal avascular zone (FAZ). (Figure 2) The VD was found to be consistently higher amongst AB++ participants in the macula inner and outer rings (p<0.05) and the FAZ area was higher in AB‐+ participants. (p<0.05)Conclusion: This study showed change in VD over time for the ONH region in participants who have been AB + for 4 years or longer. These participants further demonstrated a higher VD in the macula inner and outer rings compared to AB—and AB‐+ participants. Additional longitudinal studies where amyloid status is present for longer periods of time amongst cognitively healthy participants should be undertaken to see if these OCTA microvascular changes could be used as a biomarker in preclinical AD.
- Open Access
- 11 January 2021
- Published by Wiley in European Journal of Neurology
- Vol. 28 (5) , 1617-1626
A model for interrogating the clinico‐radiological paradox in multiple sclerosis: Internuclear ophthalmoplegia
Background and purpose: The clinico‐radiological paradox in multiple sclerosis (MS) is well recognized, relevant and yet poorly understood. The suitability of an in vivo model for the clinico‐radiological paradox was tested, using internuclear ophthalmoplegia (INO) and the medial longitudinal fasciculus (MLF).Methods: In this cross‐sectional study lesions of the MLF were rated by an experienced MS neuroradiologist blinded to all other information. The presence of an INO was objectively determined by a validated infrared oculography protocol (DEMoNS). Clinical information, including the National Eye Institute Visual Function Questionnaire, was obtained.Results: This study included 202 patients with MS. The clinico‐radiological paradox occurred in 50 patients (25%). This consisted of 45 patients having an INO without an MLF lesion and five patients with an MLF lesion but without an INO. The visual function overall score was related to the presence of an INO (p = 0.016), but not to MLF lesions seen on magnetic resonance imaging (MRI) (p = 0.207). A consensus list of potential causes for the clinico‐radiological paradox was compiled and the MRI images were deposited in a repository.Conclusion: This study provides an objective and quantitative model to investigate the clinico‐radiological paradox. Our data suggest that pathology of the MLF is more frequently detected and more clinically relevant by infrared oculography than by MLF lesion rating on MRI.
- 11 January 2021
- Published by Wiley in European Journal of Neurology
- Vol. 28 (5) , 1617-1626
Open AccessA model for interrogating the clinico‐radiological paradox in multiple sclerosis: Internuclear ophthalmoplegia
Background and purpose: The clinico‐radiological paradox in multiple sclerosis (MS) is well recognized, relevant and yet poorly understood. The suitability of an in vivo model for the clinico‐radiological paradox was tested, using internuclear ophthalmoplegia (INO) and the medial longitudinal fasciculus (MLF).Methods: In this cross‐sectional study lesions of the MLF were rated by an experienced MS neuroradiologist blinded to all other information. The presence of an INO was objectively determined by a validated infrared oculography protocol (DEMoNS). Clinical information, including the National Eye Institute Visual Function Questionnaire, was obtained.Results: This study included 202 patients with MS. The clinico‐radiological paradox occurred in 50 patients (25%). This consisted of 45 patients having an INO without an MLF lesion and five patients with an MLF lesion but without an INO. The visual function overall score was related to the presence of an INO (p = 0.016), but not to MLF lesions seen on magnetic resonance imaging (MRI) (p = 0.207). A consensus list of potential causes for the clinico‐radiological paradox was compiled and the MRI images were deposited in a repository.Conclusion: This study provides an objective and quantitative model to investigate the clinico‐radiological paradox. Our data suggest that pathology of the MLF is more frequently detected and more clinically relevant by infrared oculography than by MLF lesion rating on MRI.
- Open Access
- 4 August 2020
- Published by Wiley in Acta Ophthalmologica
- Vol. 99 (2) , E164-E170
Multidisciplinary management of auto‐immune ocular diseases in adult patients by ophthalmologists and rheumatologists
Purpose: Management of chronic vision threatening auto‐immune ocular diseases (AIOD, e.g. uveitis, scleritis) can be challenging. Guidelines recommend a multidisciplinary approach (MDA) with ophthalmologists and rheumatologists, to enhance the recognition of systemic diseases and guide the use of immunosuppressives. However, the indications and results of such an approach have not yet been studied.Methods: A monocentre, retrospective chart review of all patients treated in a MDA between ophthalmologists and rheumatologists, in a Dutch tertiary center. The collaboration was twofold: a combined multidisciplinary team meeting every 2 weeks, and an ophthalmology‐dedicated rheumatology outpatient clinic. Primary endpoints of this descriptive study were as follows: indications for MDA, new diagnoses of systemic auto‐immune diseases and changes in systemic immunosuppression and prednisone dosages.Results: In total, 157 adults (mean age 46 years, 57% female, median disease duration 19 months) were included, mainly with uveitis (74%) and scleritis (12%). Multidisciplinary approach (MDA)‐indications included diagnostic workup (32%), treatment support (44%), diagnostic‐and‐treatment support (10%) and side effects (8%). A systemic disease was newly diagnosed in eight and already present in 34 patients. At baseline, 54 patients used oral prednisone at >7.5 mg/day. Non‐corticoid immunosuppressives, mostly methotrexate, were started in 41% of the patients. During follow‐up, systemic prednisone was lowered to ≤7.5 mg/day in 68% of the patients.Conclusion: This evaluation of an MDA‐programme in the management of AIOD demonstrated its added value. Mainly, it addressed the high demand for support in managing systemic immunosuppression, resulting in significant corticosteroid tapering. In addition, it resulted in the recognition of underlying systemic diseases.
- 4 August 2020
- Published by Wiley in Acta Ophthalmologica
- Vol. 99 (2) , E164-E170
Open AccessMultidisciplinary management of auto‐immune ocular diseases in adult patients by ophthalmologists and rheumatologists
Purpose: Management of chronic vision threatening auto‐immune ocular diseases (AIOD, e.g. uveitis, scleritis) can be challenging. Guidelines recommend a multidisciplinary approach (MDA) with ophthalmologists and rheumatologists, to enhance the recognition of systemic diseases and guide the use of immunosuppressives. However, the indications and results of such an approach have not yet been studied.Methods: A monocentre, retrospective chart review of all patients treated in a MDA between ophthalmologists and rheumatologists, in a Dutch tertiary center. The collaboration was twofold: a combined multidisciplinary team meeting every 2 weeks, and an ophthalmology‐dedicated rheumatology outpatient clinic. Primary endpoints of this descriptive study were as follows: indications for MDA, new diagnoses of systemic auto‐immune diseases and changes in systemic immunosuppression and prednisone dosages.Results: In total, 157 adults (mean age 46 years, 57% female, median disease duration 19 months) were included, mainly with uveitis (74%) and scleritis (12%). Multidisciplinary approach (MDA)‐indications included diagnostic workup (32%), treatment support (44%), diagnostic‐and‐treatment support (10%) and side effects (8%). A systemic disease was newly diagnosed in eight and already present in 34 patients. At baseline, 54 patients used oral prednisone at >7.5 mg/day. Non‐corticoid immunosuppressives, mostly methotrexate, were started in 41% of the patients. During follow‐up, systemic prednisone was lowered to ≤7.5 mg/day in 68% of the patients.Conclusion: This evaluation of an MDA‐programme in the management of AIOD demonstrated its added value. Mainly, it addressed the high demand for support in managing systemic immunosuppression, resulting in significant corticosteroid tapering. In addition, it resulted in the recognition of underlying systemic diseases.
- Open Access
- 28 April 2020
- Published by Springer Nature in BMC Geriatrics
- Vol. 20 (1) , 1-9
Ocular biomarkers for cognitive impairment in nonagenarians; a prospective cross-sectional study
Ocular imaging receives much attention as a source of potential biomarkers for dementia. In the present study, we analyze these ocular biomarkers in cognitively impaired and healthy participants in a population aged over 90 years (= nonagenarian), and elucidate the effects of age on these biomarkers. For this prospective cross-sectional study, we included individuals from the EMIF-AD 90+ study, consisting of a cognitively healthy (N = 67) and cognitively impaired group (N = 33), and the EMIF-AD PreclinAD study, consisting of cognitively healthy controls aged ≥60 (N = 198). Participants underwent Optical Coherence Tomography (OCT) and fundus photography of both eyes. OCT was used to asses total and individual inner retinal layer thickness in the macular region (Early Treatment Diabetic Retinopathy Study circles) as well as peripapillary retinal nerve fiber layer thickness, fundus images were analyzed with Singapore I Vessel Assessment to obtain 7 retinal vascular parameters. Values for both eyes were averaged. Differences in ocular biomarkers between the 2 nonagenarian groups were analyzed using linear regression, differences between the individual nonagenarian groups and controls were analyzed using generalized estimating equations. Ocular biomarkers did not differ between the healthy and cognitively impaired nonagenarian groups. 19 out of 22 ocular biomarkers assessed in this study differed between either nonagenarian group and the younger controls. The ocular biomarkers assessed in this study were not associated with cognitive impairment in nonagenarians, making their use as a screening tool for dementing disorders in this group limited. However, ocular biomarkers were significantly associated with chronological age, which were very similar to those ascribed to occur in Alzheimer’s Disease.
- 28 April 2020
- Published by Springer Nature in BMC Geriatrics
- Vol. 20 (1) , 1-9
Open AccessOcular biomarkers for cognitive impairment in nonagenarians; a prospective cross-sectional study
Ocular imaging receives much attention as a source of potential biomarkers for dementia. In the present study, we analyze these ocular biomarkers in cognitively impaired and healthy participants in a population aged over 90 years (= nonagenarian), and elucidate the effects of age on these biomarkers. For this prospective cross-sectional study, we included individuals from the EMIF-AD 90+ study, consisting of a cognitively healthy (N = 67) and cognitively impaired group (N = 33), and the EMIF-AD PreclinAD study, consisting of cognitively healthy controls aged ≥60 (N = 198). Participants underwent Optical Coherence Tomography (OCT) and fundus photography of both eyes. OCT was used to asses total and individual inner retinal layer thickness in the macular region (Early Treatment Diabetic Retinopathy Study circles) as well as peripapillary retinal nerve fiber layer thickness, fundus images were analyzed with Singapore I Vessel Assessment to obtain 7 retinal vascular parameters. Values for both eyes were averaged. Differences in ocular biomarkers between the 2 nonagenarian groups were analyzed using linear regression, differences between the individual nonagenarian groups and controls were analyzed using generalized estimating equations. Ocular biomarkers did not differ between the healthy and cognitively impaired nonagenarian groups. 19 out of 22 ocular biomarkers assessed in this study differed between either nonagenarian group and the younger controls. The ocular biomarkers assessed in this study were not associated with cognitive impairment in nonagenarians, making their use as a screening tool for dementing disorders in this group limited. However, ocular biomarkers were significantly associated with chronological age, which were very similar to those ascribed to occur in Alzheimer’s Disease.
- Open Access
- 16 April 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (4) , e0231552
The spatial relation of diabetic retinal neurodegeneration with diabetic retinopathy
Diabetic retinal neurodegeneration (DRN) has been demonstrated in eyes of patients with diabetes mellitus (DM), even in the absence of diabetic retinopathy (DR). However, no studies have looked at the rate of change in retinal layers and presence/development of DR over time per quadrant of the macula. In this longitudinal study, we aimed to clarify whether the rate of DRN is associated with the development/presence of DR within 4 different quadrants of the retina. 80 eyes of 40 patients with type 1 DM and no/minimal DR were included. At 4 visits over 6 years, SD-OCT and fundus images were acquired. Thickness of the Retinal Nerve Fiber Layer (RNFL), Ganglion Cell Layer (GCL) and Inner Plexiform Layer (IPL) was measured in a 1-6mm circle around the fovea overall and for each quadrant (superior, nasal, inferior, temporal). Fundus images were scored for the presence/absence of DR in these areas. Multilevel analyses were performed to determine the rate of change for each layer overall and per quadrant for eyes/quadrants without and with DR during the follow-up period. RNFL and GCL showed significant thinning over time, IPL significant thickening. These changes were more pronounced for GCL and IPL in eyes/quadrants with DR during the follow-up period. RNFL and GCL both showed thinning over time, which was more pronounced in eyes with DR for GCL. This holds true even in regional parts of the retina, as quadrant analyses showed similar results, showing that structural DRN is associated with DR per quadrant independently.
- 16 April 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (4) , e0231552
Open AccessThe spatial relation of diabetic retinal neurodegeneration with diabetic retinopathy
Diabetic retinal neurodegeneration (DRN) has been demonstrated in eyes of patients with diabetes mellitus (DM), even in the absence of diabetic retinopathy (DR). However, no studies have looked at the rate of change in retinal layers and presence/development of DR over time per quadrant of the macula. In this longitudinal study, we aimed to clarify whether the rate of DRN is associated with the development/presence of DR within 4 different quadrants of the retina. 80 eyes of 40 patients with type 1 DM and no/minimal DR were included. At 4 visits over 6 years, SD-OCT and fundus images were acquired. Thickness of the Retinal Nerve Fiber Layer (RNFL), Ganglion Cell Layer (GCL) and Inner Plexiform Layer (IPL) was measured in a 1-6mm circle around the fovea overall and for each quadrant (superior, nasal, inferior, temporal). Fundus images were scored for the presence/absence of DR in these areas. Multilevel analyses were performed to determine the rate of change for each layer overall and per quadrant for eyes/quadrants without and with DR during the follow-up period. RNFL and GCL showed significant thinning over time, IPL significant thickening. These changes were more pronounced for GCL and IPL in eyes/quadrants with DR during the follow-up period. RNFL and GCL both showed thinning over time, which was more pronounced in eyes with DR for GCL. This holds true even in regional parts of the retina, as quadrant analyses showed similar results, showing that structural DRN is associated with DR per quadrant independently.
- 1 March 2020
- Published by Elsevier in Vision Research
- Vol. 168, 33-41
Saccadic delay in multiple sclerosis: A quantitative description
- 1 March 2020
- Published by Elsevier in Vision Research
- Vol. 168, 33-41
Saccadic delay in multiple sclerosis: A quantitative description
- 1 July 2019
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 402, 167-174
Saccadic fatigability in the oculomotor system
- 1 July 2019
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 402, 167-174
Saccadic fatigability in the oculomotor system
- Open Access
- 14 May 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 92 (20) , e2299-e2308
Diagnosing and quantifying a common deficit in multiple sclerosis
Objective We present an objective and quantitative approach for diagnosing internuclear ophthalmoplegia (INO) in multiple sclerosis (MS). Methods A validated standardized infrared oculography protocol (DEMoNS [Demonstrate Eye Movement Networks with Saccades]) was used for quantifying prosaccades in patients with MS and healthy controls (HCs). The versional dysconjugacy index (VDI) was calculated, which describes the ratio between the abducting and adducting eye. The VDI was determined for peak velocity, peak acceleration, peak velocity divided by amplitude, and area under the curve (AUC) of the saccadic trajectory. We calculated the diagnostic accuracy for the several VDI parameters by a receiver operating characteristic analysis comparing HCs and patients with MS. The National Eye Institute Visual Function Questionnaire–25 was used to investigate vision-related quality of life of MS patients with INO. Results Two hundred ten patients with MS and 58 HCs were included. The highest diagnostic accuracy was achieved by the VDI AUC of 15° horizontal prosaccades. Based on a combined VDI AUC and peak velocity divided by amplitude detection, the prevalence of an INO in MS calculated to 34%. In the INO group, 35.2% of the patients with MS reported any complaints of double vision, compared to 18.4% in the non-INO group (p = 0.010). MS patients with an INO had a lower overall vision-related quality of life (median 89.9, interquartile range 12.8) compared to patients without an INO (median 91.8, interquartile range 9.3, p = 0.011). Conclusions This study provides an accurate quantitative and clinically relevant definition of an INO in MS. This infrared oculography-based INO standard will require prospective validation. The high prevalence of INO in MS provides an anatomically well described and accurately quantifiable model for treatment trials in MS.
- 14 May 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 92 (20) , e2299-e2308
Open AccessDiagnosing and quantifying a common deficit in multiple sclerosis
Objective We present an objective and quantitative approach for diagnosing internuclear ophthalmoplegia (INO) in multiple sclerosis (MS). Methods A validated standardized infrared oculography protocol (DEMoNS [Demonstrate Eye Movement Networks with Saccades]) was used for quantifying prosaccades in patients with MS and healthy controls (HCs). The versional dysconjugacy index (VDI) was calculated, which describes the ratio between the abducting and adducting eye. The VDI was determined for peak velocity, peak acceleration, peak velocity divided by amplitude, and area under the curve (AUC) of the saccadic trajectory. We calculated the diagnostic accuracy for the several VDI parameters by a receiver operating characteristic analysis comparing HCs and patients with MS. The National Eye Institute Visual Function Questionnaire–25 was used to investigate vision-related quality of life of MS patients with INO. Results Two hundred ten patients with MS and 58 HCs were included. The highest diagnostic accuracy was achieved by the VDI AUC of 15° horizontal prosaccades. Based on a combined VDI AUC and peak velocity divided by amplitude detection, the prevalence of an INO in MS calculated to 34%. In the INO group, 35.2% of the patients with MS reported any complaints of double vision, compared to 18.4% in the non-INO group (p = 0.010). MS patients with an INO had a lower overall vision-related quality of life (median 89.9, interquartile range 12.8) compared to patients without an INO (median 91.8, interquartile range 9.3, p = 0.011). Conclusions This study provides an accurate quantitative and clinically relevant definition of an INO in MS. This infrared oculography-based INO standard will require prospective validation. The high prevalence of INO in MS provides an anatomically well described and accurately quantifiable model for treatment trials in MS.
- Open Access
- 6 May 2019
- Published by Wiley in Acta Ophthalmologica
- Vol. 97 (8) , 798-804
Retinal layer thickness in preclinical Alzheimer's disease
Purpose: There is urgent need for non‐invasive diagnostic biomarkers in the preclinical phase of Alzheimer's Disease (AD). Several studies suggest that retinal thickness is reduced in AD. Here, we aim to test the diagnostic value of retinal thickness in preclinical AD, as defined by cognitively normal individuals with amyloid pathology on PET.Methods: One hundred and sixty five cognitively healthy monozygotic twins aged ≥ 60 were included from the Netherlands Twin Register taking part in the European Medical Information Framework for Alzheimer's Disease PreclinAD study. Participants underwent [18F] flutemetamol PET that was visually rated for presence or absence of cortical amyloid beta (Aβ). Binding potential (BPND) was calculated as continuous measure for Aβ. Spectral Domain OCT was used to asses total and individual inner retinal layer thickness in the macular region (ETDRS circles) as well as peripapillary retinal nerve fibre layer (pRNFL) thickness. Differences between Aβ+ and Aβ− individuals and associations between BPND and retinal thickness were analyzed.Results: No differences were found in retinal layer thickness in the macula or pRNFL between Aβ+ and Aβ− individuals. A positive associations between BPND and macular total retinal thickness was observed in the inner ring (p = 0.018), but this was not statistically significant after correction for multiple testing (p = 0.144). Brain/eye parameters had moderate to high intra‐twin correlations (p < 0.001) except visual rating score of Aβ, which did not correlate (r = 0.21, p = 0.068).Conclusion: Variation in retinal thickness likely reflects genetic differences between individuals, but cannot discriminate between healthy and preclinical AD cases, making its use as biomarker in these early stages limited.
- 6 May 2019
- Published by Wiley in Acta Ophthalmologica
- Vol. 97 (8) , 798-804
Open AccessRetinal layer thickness in preclinical Alzheimer's disease
Purpose: There is urgent need for non‐invasive diagnostic biomarkers in the preclinical phase of Alzheimer's Disease (AD). Several studies suggest that retinal thickness is reduced in AD. Here, we aim to test the diagnostic value of retinal thickness in preclinical AD, as defined by cognitively normal individuals with amyloid pathology on PET.Methods: One hundred and sixty five cognitively healthy monozygotic twins aged ≥ 60 were included from the Netherlands Twin Register taking part in the European Medical Information Framework for Alzheimer's Disease PreclinAD study. Participants underwent [18F] flutemetamol PET that was visually rated for presence or absence of cortical amyloid beta (Aβ). Binding potential (BPND) was calculated as continuous measure for Aβ. Spectral Domain OCT was used to asses total and individual inner retinal layer thickness in the macular region (ETDRS circles) as well as peripapillary retinal nerve fibre layer (pRNFL) thickness. Differences between Aβ+ and Aβ− individuals and associations between BPND and retinal thickness were analyzed.Results: No differences were found in retinal layer thickness in the macula or pRNFL between Aβ+ and Aβ− individuals. A positive associations between BPND and macular total retinal thickness was observed in the inner ring (p = 0.018), but this was not statistically significant after correction for multiple testing (p = 0.144). Brain/eye parameters had moderate to high intra‐twin correlations (p < 0.001) except visual rating score of Aβ, which did not correlate (r = 0.21, p = 0.068).Conclusion: Variation in retinal thickness likely reflects genetic differences between individuals, but cannot discriminate between healthy and preclinical AD cases, making its use as biomarker in these early stages limited.